Blood transfusions are associated with adverse physiologic effects and increased cost, and therefore reduction of blood product use during surgery is a desirable goal for all patients. Cardiac surgery is a major consumer of donor blood products, especially when cardiopulmonary bypass (CPB) is used, because hematocrit drops precipitously during CPB due to blood loss and blood cell dilution. Advanced age, low preoperative red blood cell volume (preoperative anemia or small body size), preoperative antiplatelet or antithrombotic drugs, complex or re-operative procedures or emergency operations, and patient comorbidities were identifi ed as important transfusion risk indicators in a report recently published by the Society of Cardiovascular Anesthesiologists. This report also identifi ed several pre-and intraoperative interventions that may help reduce blood transfusions, including off-pump procedures, preoperative autologous blood donation, normovolemic hemodilution, and routine cell saver use.
INTRODUCTION
Transfusion of blood products is associated with adverse effects and costs. Consequently, reduction of blood transfusions during surgery through preservation of a patient's own red cells has been identifi ed as a relevant, important goal [Goodnough 2003 ]. Strategies aimed at reducing blood product utilization are particularly important in cardiac surgery, especially when cardiopulmonary bypass (CPB) is used, because concurrent blood loss and red blood cell dilution due to positive fl uid balance during CPB result in precipitous hematocrit drop and need for transfusion. Published data suggest that simple behavioral interventions, such as education, transfusion guidelines, transfusion audits, and use of transfusion forms with highlighted transfusion criteria, effectively alter physician transfusion practices and reduce blood utilization [Tinmouth 2005 ]. In a report by the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists [Ferraris 2007 ], advanced age, low preoperative red blood cell volume (preoperative anemia or small body size), preoperative antiplatelet or antithrombotic drugs, complex or re-operative procedures or emergency operations, and non-cardiac patient comorbidities were identifi ed as important indicators of risk for transfusion. In the same report, careful literature review revealed several simple preoperative and intraoperative interventions likely to reduce blood transfusion; these interventions include use of drugs that increase preoperative blood volume (eg, erythropoietin) or decrease postoperative bleeding (eg, antifi brinolytics), limitation of antithrombotic drugs, selective use of off-pump coronary artery bypass graft surgery (OPCABG), preoperative autologous blood donation, normovolemic hemodilution, and routine use of cell-saving devices. Existing guidelines emphasize the signifi cance of a multimodal approach to blood conservation, with high-risk patients receiving all available interventions under appropriate transfusion algorithms [ASA Task Force on Perioperative Blood Transfusion and Adjuvant Therapies 2006; Ferraris 2007] . Adoption of blood conservation therapies has been slow despite their documented effectiveness [Goodnough 1997; Hutchinson 2001] . Clinical judgement is of paramount importance in evaluating the risk versus benefi t of transfusion for each individual patient in an attempt to maintain vital organ perfusion while avoiding unnecessary transfusions [Spiess 2005] .
Based on an up-to-date literature review and our own clinical experiences, this review discusses currently available techniques that can be used intraoperatively by anesthesiologists in an attempt to decrease blood product utilization during cardiac surgery.
RESULTS
The search strategy yielded 379 abstracts, case studies, and case reports for initial consideration. All records were entered into a Reference Manager® v. 12 database (Thomson Reuters, New York, New York, USA), and 78 articles were found to be of relevance. The full text of these 78 original articles, review articles, case series, case reports, and editorials was retrieved and examined by the above authors (GV and MK), and any disagreements were resolved by discussion. Finally, 61 articles were included in this narrative review.
EXTRACORPOREAL CIRCULATION AND HEMODILUTION
Although priming fl uid added to the circulation on CPB initiation does not signifi cantly affect circulating erythrocyte mass, it results in acute dilutional anemia, which can be exacerbated by pre-CPB fl uid administration. This red blood cell dilution becomes a primary determinant of transfusion, because hemoglobin or hematocrit values are often used as "transfusion triggers" in clinical practice [Paone 1994; DeFoe 2001] , even though use of these "transfusion triggers" is not supported by high-level evidence [Herbert 2004; Tinmouth 2005] . We found 14 articles that focus on the safety of hemodilution during CPB (Table 1) [Lowenstein 1981; Cosgrove 1985; Utley 1990; Paone 1994; DeFoe 2001; Karkouti 2001; Engoren 2002; Habib 2003; Swaminathan 2003; Arora 2004; Herbert 2004; Dial 2005; Habib 2005; Tinmouth 2005 ]. Five of these articles suggest that increased or extreme hemodilution is associated with worse organ dysfunction/injury and increased morbidity [Shinoka 1996; DeFoe 2001; Habib 2003; Habib 2005; Swaminathan 2003 ]. Eight articles and 1 animal study supports the safety of the increased hemodilution methods during CPB [Lowenstein 1981; Cosgrove 1985; Utley 1990; Paone 1994; Karkouti 2001; Engoren 2002; Arora 2004; Dial 2005; Tinmouth 2005] , and 1 article is an editorial and does not support hemoglobin (Hb) < 7 g/dL in the general population [Hebert 2004] . Preoperative Hb 12.0 or less, emergent operation, renal failure, female sex, age 70 years or older, left ventricular ejection fraction 0.40 or less, redo procedure, and low body surface area are independent predictors of erythrocyte transfusion in cardiac surgery according to an internally validated logistic regression risk model. This model is a sensitive and specifi c predictor of allogeneic blood product use in patients undergoing isolated CABG [Arora 2004] . Utilization of this model and also some other models with similar information allows for preoperative risk stratification and may allow for more rational resource allocation of costly blood conservation strategies and blood bank resources [Cosgrove 1985; DeFoe 2001; Karkouti 2001; Engoren 2002; Arora 2004; Dial 2005] . Blood loss and hemodilution have a greater impact on Hb concentration in female patients and in patients with low body surface area, compared to men with average somatometric values [DeFoe 2001] . Because these observations underline the impact of hemodilution on blood product use, avoidance of hemodilution is an important step toward blood conservation during cardiac surgery [Tempe 2005] , and studies evaluating hemodilution during CPB are currently underway (www.clinicaltrials.gov NCT00660608). Hb or hematocrit values are even less appropriate indicators of the need to transfuse in iatrogenic hemodilution cases, where accurate blood loss and intravascular blood volume estimates are diffi cult or impossible. During CPB, systemic perfusion and oxygenation are provided under conditions of heparinization, hemodilution with reduced blood viscosity, non-pulsatile blood fl ow, and hypothermia. These conditions signifi cantly alter systemic physiology and formed blood elements [Utley 1990 ], so oxygen tissue delivery may remain adequate with hematocrit values well below baseline physiologic levels. Consequently, other physiologic variables, such as whole body oxygen-carrying capacity, oxygen consumption, oxygen extraction ratios, and oxygen delivery may be more appropriate indicators of need to transfuse in such cases. Hb values as low as 5.0 g/dL have been shown to provide adequate oxygen delivery during CPB [Lowenstein 1981; Cosgrove 1985] . All the above studies do not exactly support the reduction of blood product transfusions; instead they give us predictive models and information that we can use and reduce blood product transfusions in some patient subgroups. This is very important not only for the reduction of the transfusions cost but also because transfusions may be associated with increased long-term mortality [Engoren 2002] .
Although these observations may create a sense of safety and decrease the "transfusion threshold" to lower hematocrit values, other clinical data [Habib 2003; Swaminathan Table 1 . Because volume load is modifi able, net fl uid balance during operations under CPB can be reduced by interventions such as prime volume minimization with or without use of hyperoncotic solutions, retrograde autologous CPB circuit priming, cell salvage techniques, and use of plasma concentration fi lters.
PRIME VOLUME REDUCTION
Low prime volume is of primary importance for hemodilution attenuation, and therefore numerous efforts have been made to minimize circuit volume. Conventional circuit volume can exceed 1400 mL for the pump and the oxygenator, but the volume needed is reduced to 450 mL in newer integrated circuits combining the centrifugal pump and the oxygenator. We examined 7 articles that focus on the effectiveness and safety of the minimized circuits (MCs) ( Table  2) Cardiac surgery is particularly challenging in Jehovah's Witness patients, especially children, because these patients reject not only homologous transfusion, but also re-transfusion of autologous blood temporarily separated from their own circulation. In one report, open-heart surgery was successfully performed in 3 Jehovah's Witness infants (body weight between 3.1 and 4.5 kg) without any blood component transfusion using a small-volume CPB circuit with a 200-mL priming volume [Boettcher 2005 ].
Generally, CPB and CPB circuits trigger a signifi cant systemic infl ammatory response through complement activation and pro-infl ammatory cytokine release [Laffey 2002 ]. Interestingly, data suggest that use of MCs reduces infl ammatory reaction, activation of coagulation, and fi brinolysis and that their benefi cial effects on infl ammation and hemodilution may reduce the need for allogeneic blood transfusions [Fromes 2002 
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their use is rapidly increasing as more and more anesthesiologists, perfusionists, and surgeons are trained and become aware of their advantages.
The use of low prime and minimized extracorporeal bypass circuits in order to reduce hemodilution during CPB is classifi ed in the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists report in Class IIb (level of evidence B) as not unreasonable for blood conservation [Ferraris 2007 ]. The true impact of MCs on transfusion infl ammatory response and outcome, however, are largely unknown and deserve further investigation. The articles that focus on the effectiveness and safety of MCs are presented in Table 2 .
HYPERONCOTIC CARDIOPULMONARY BYPASS PRIME
Marked colloid osmotic pressure (COP) reduction due to hemodilution upon CPB initiation may be a signifi cant factor adversely affecting post-CPB organ function. Acute COP reduction causes an imbalance between microvascular net fi ltration and lymphatic interstitial fl uid removal, thereby leading to edema formation. Extravascular lung water excess and myocardial edema can contribute to cardiopulmonary dysfunction [Boldt 1986; Goto 1991; Boldt 1999] . Presently, the optimal priming fl uid composition for the CPB circuit is unknown, and the impact of priming fl uid composition on post-CPB organ dysfunction remains controversial. In Table 2 , 4 prospective RCTs that compare different priming fl uids are presented [Lindberg 1985; Sade 1985; Jansen 1996; Eising 2001] . Three of these studies evaluating colloid as priming fl uid failed to show any clinical benefi t or outcome improvement [Lindberg 1985; Sade 1985; Eising 2001 ], perhaps because (1) COP of these hyperoncotic priming solutions was still less than physiologic, and (2) crystalloid cardioplegia was used. Currently, because many centers use blood cardioplegic solution drained from the reservoir, COP reduction may be avoided with hyperoncotic priming. A RCT of 20 patients undergoing elective coronary artery surgery using heparin-coated circuits and crystalloid cardioplegia showed improved clinical performance and shorter postoperative hospital stay in the colloid CPB prime group, but did not show reduced blood product transfusions [Jansen 1996 ].
In a later study comparing hydroxyethyl starch (HES) versus crystalloid, COP reduction and net fl uid balance were signifi cantly reduced and hemodynamic parameters and functional respiratory variables such as AaDO 2 and Qs/Qt were improved in the HES group [Lindberg 1985 ]. Hb and hematocrit values 2 and 4 hours after surgery did not differ between groups, however, and despite a trend toward increased blood loss in the HES group, outcome did not differ between groups. At present, use of hyperoncotic priming solutions and attenuation of COP reduction do not have any documented impact on blood product use in cardiac surgery, but studies addressing this important issue are currently underway (www.clinicaltrials.gov NCT00182377).
RETROGRADE AUTOLOGOUS PRIMING OF THE CARDIOPULMONARY BYPASS CIRCUIT
Retrograde autologous priming (RAP) of the CPB circuit was fi rst described in 1960 [Panico 1960 ] and revived in the late 1990s [Rosengart 1998 ] in an attempt to limit hemodilution on CPB initiation. RAP involves replacement of the crystalloid prime by the patient's own blood. After arterial and venous cannulae are in place, up to 1 L of crystalloid prime is slowly drained into a recirculation bag and replaced by the patient's blood immediately before CPB initiation [Rosengart 1998 ]. A 1000-mL blood transfer bag is connected to the venous line, and RAP is performed in 3 basic steps. First, crystalloid is displaced from the arterial line into the blood transfer bag by blood allowed to fl ow backwards from the aorta into the arterial line and fi lter. Next, crystalloid in the venous reservoir and oxygenator is displaced by blood fl owing backwards from the aorta. Finally, the remaining prime is displaced from the venous line into the bag on CPB initiation. Approximately 300 mL of CPB circuit prime volume is replaced in each step, and the entire RAP process can be completed in 5 to 8 minutes. This technique maintains COP and reduces extravascular lung water compared with standard priming techniques.
However, hypovolemia, as blood is drained from the patient into the arterial and venous lines, can result in hemodynamic instability. Hypotension can be treated with phenylephrine (bolus or infusion) and/or crystalloid administration during the (usually brief) period before the pump reaches acceptable fl ow for organ perfusion, but crystalloid administration at this stage mitigates the RAP effect. If hemodynamic instability persists despite these measures, the RAP process must be terminated. Because RAP generally causes hypovolemia in the patient-circuit system, the perfusionist must be trained in its use and remain vigilant in order to preserve organ perfusion.
Eight studies examine the effectiveness and safety of RAP (Table 2) [Parrot 1991; Jansen 1995; Rosengart 1998; Shapira 1998; Rousou 1999; Dalrymple-Hay 2001; Balachandran 2002; . The effi cacy of RAP in reducing the number of patients transfused and/or total blood product use has been demonstrated in almost all of these studies [Jansen 1993; Jansen 1995; Rosengart 1998; Shapira 1998; Rousou 1999; Dalrymple-Hay 2001; Balachandran 2002] . A retrospective study, however, showed minimal, nonsignifi cant reduction in packed red cell (PRC) use with routine RAP , with 44% of patients in the RAP group receiving PRCs versus 51% in the control group. Patients with larger initial red cell mass derived a greater benefi t from RAP, but interpretation of these results is limited by retrospective study design. In a later analysis, the same investigators found decreased incidence of postoperative cardiac arrest in the RAP group and no change in other adverse events, thus suggesting that RAP is a safe technique [Murphy 2006 ]. The observed reduction in blood product transfusions makes the technique part of the blood conservation strategies [Rousou 1999 ]. Other investigators observed no effect of RAP on postoperative or total transfusion requirements and concluded that RAP, by reducing crystalloid fl uid administration and COP reduction during CPB, reduces post-CPB weight gain [Eising 2003 ]; however, these trials excluded patients at high risk for transfusion and were limited by small RAP group size.
A database study attempted to determine the effect of different prime volumes on postoperative hyperdynamic response by comparing patients with large CPB prime (2350 mL) versus patients with small (1400 mL) CPB prime volume [Jansen 1995] . COP was higher, fl uid balance was less positive, and the hyperdynamic response was partly attenuated in the small prime volume group, and the authors concluded that using small prime volumes can reduce blood product use. In 2 other RCTs, use of RAP signifi cantly reduced allogeneic blood transfusion frequency [Jansen 1991; DalrympleHay 2001] . Studies investigating the impact of small volume CPB circuits in combination with retrograde autologous CPB circuit priming are currently underway (www.clinicaltrials. gov NCT00646373). Based on current evidence, retrograde autologous CPB circuit priming is classifi ed as "not unreasonable" (Class IIb, level of evidence B) for blood conservation in the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists practice guidelines [Ferraris 2007 ].
RED CELL SAVING
Autologous blood cell salvage is used routinely in many parts of the world in cardiac [ASA Task Force on Perioperative Blood Transfusion and Adjuvant Therapies 2006] and other high-risk operations [Goodnough 2003 ]. We studied 3 reviews [Goodnough 2003 ; ASA Task Force on Perioperative Blood Transfusion and Adjuvant Therapies 2006; Ferraris 2007] and 17 clinical trials [Moran 1978; Thurer 1979; Cordell 1981; Winton 1982; Keeling 1983; Mayer 1985; Dietrich 1989; Hall 1990; Merville 1991; Despotis 1996; Tempe 1996; Lee 1997; Gray 2001; Tempe 2001; Daane 2003; Svenmarker 2003; (Table 3) . Most of the trials are RCTs [Moran 1978; Thurer 1979; Mayer 1985; Dietrich 1989; Merville 1991; Tempe 1996; Tempe 2001; Daane 2003; Svenmarker 2003; . Overall, 16 studies and reviews show positive results. Intraoperative autotransfusion with a cell saver involves recovery of the patient's own blood from the surgical wound, washing and/or fi ltering, and re-infusion into the circulation. According to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists guidelines, routine use of red cell saving is helpful for blood conservation in cardiac operations using CPB, except in cases of infection or malignancy (Class A, level of evidence A) [Ferraris 2007] . Today, cell saving devices can process quickly even small amounts of blood, require small priming volumes, continuously return high quality blood during and after surgery, and can collect blood not only during heparinization, but also when there is no heparin effect (eg, during internal mammary artery preparation). Several reports document the safety of the cell saver and support its routine use in cardiac surgery as a means to reduce blood transfusion [Moran 1978; Cordell 1981; Winton 1982; Keeling 1983; Mayer 1985; Hall 1990; Lee 1997; Tempe 2001] , and intraoperative autologous blood donation combined with cell saver use decreases transfusion requirements in small-size patients (mean body weight of 45 kg) [Tempe 1996 ]. In a recent RCT, patients scheduled for CABG were randomized to autotransfusion (receiving autotransfused washed blood from intraoperative cell salvage and postoperative mediastinal fl uid cell salvage, n = 98), or control (receiving stored homologous blood only, n = 102). Postoperative blood loss, fl uid requirements, and adverse events did not differ between groups, but patients in the autotransfusion group were signifi cantly less likely to receive homologous blood transfusions and received signifi cantly fewer units of blood. Autotransfusion did not produce any signifi cant derangement on thromboelastograph or laboratory coagulation profi le (prothrombin time, activated partial thromboplastin time, fi brinogen, and fi brinogen D-dimer levels) . Concern has been raised regarding transfusion of cytokines through autologous shed blood [Arnestad 1994 ], but this concern is diminished because modern salvage is associated with reduced circulating markers of systemic infl ammation [Perttila 1995; Amand 2002; Jewell 2003; Svenmarker 2003 ].
After weaning from CPB, perfusionists drain the CPB circuit to the saving apparatus in order to limit red cell wasting. Salvage of CPB circuit blood is a reasonable attempt at blood conservation (level of evidence C) [Tinmouth 2005] and is routinely performed in many centers. In one RCT, residual pump blood processed with an autotransfusion system was better than unprocessed blood in terms of complement activation, coagulation factors, and stimulation of interleukin-6 (IL-6) and IL-8 [Walpoth 1999 ]. The better postoperative clinical course in the processed blood group patients was attributed to reduced load of retransfused activated mediators; however, extensive use of cell salvage systems to process the extracorporeal circuit content after CPB discontinuation may lead to coagulation factor and platelets loss, resulting in a bleeding diathesis [Despotis 1996 ]. Existing studies cannot provide conclusive answers, so the impact of CPB circuit blood salvage on allogeneic blood transfusion requirements remains unclear [Dietrich 1989; Merville 1991; Daane 2003 ]. It is noteworthy that, according to recent data, savers used in combination with leukocyte depletion fi lters or salvaged blood irradiation may be of benefi t in oncologic surgery [Hansen 1999; Thomas 1999; Gray 2001] , and therefore the dogma that salvage is contraindicated in malignancy is now questioned.
Aspiration of mediastinal blood from the operative fi eld with the cardiotomy suction, followed by direct reinfusion is performed routinely and can occasionally be life-saving ("sucker bypass"). However, "uncontrolled" cardiotomy suction during prolonged CPB (>3 hours) may be associated with increased postoperative bleeding [Boonstra 1985 ]. Cardiotomy suction in combination with a cell saving apparatus is routinely practiced worldwide. In most cases, blood from the fi eld is processed by the saver when there is no heparin, whereas during heparinization cardiotomy blood is directly reinfused. Direct reinfusion of mediastinal blood drained postoperatively from the chest tube is not recommended and may cause harm (Level of evidence B) [Ferraris 2007 ]. In cases of extensive postoperative bleeding, collected blood must be processed by a saver before reinfusion. In conclusion, because approximately half of the blood suctioned from the patient is ultimately reconstituted with usual red blood cell conservation protocols, appropriate cell saver use during and after cardiac surgery may reduce overall transfusion requirements.
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PLASMA CONCENTRATION FILTERS
Filters are often used in cardiac surgery to remove excess fl uid administered on CPB initiation. Hemoconcentration is based on transmembrane pressure-driven ultrafi ltration and involves the separation of plasma fl uid and low molecular solute substances from diluted blood with a membrane fi ltering blood components and proteins. There are no absolute contraindications to hemoconcentration, but infection, hemolysis, and embolism are potential complications. To avoid hemolysis, fi lters should be primed before running, with priming volume ranging, depending on device type, between 15 and 100 mL. Of note, addition of crystalloid to the CPB circuit is often required in order to maintain adequate circulating volume during hemofi ltration, but may counteract the favorable hemofi ltration effect on hemodilution. The net effect of hemofi ltration on total body water reduction and transfusion needs is unclear: We present 4 studies [Babka 1997; Grunenfelder 2000; Raman 2003; Boodhwani 2010] with negative or unclear results (Table 3) . A RCT of 60 patients assigned to hemofi ltration versus standard CPB did not show any allogeneic blood product use reduction, and the researchers concluded that routine ultrafi ltration during coronary artery bypass surgery with CPB does not improve quality of care [Babka 1997 ]. Another retrospective study comparing 61 patients treated with hemofi ltration versus 57 patients treated with CPB alone showed a trend toward decreased bleeding during high-risk cardiac surgery in the hemofi ltration group [Raman 2003 ], with this benefi cial hemofi ltration effect possibly related to infl ammatory mediator removal and improved hemodynamic indices. The hemofi ltration effect on infl ammatory response seems more prominent with modifi ed fi lters. A RCT of 97 patients compared a modifi ed fi lter to conventional CPB and showed no difference in blood loss between groups, but adhesion molecules and cytokines were signifi cantly reduced in the fi lter group [Grunenfelder 2000] .
A very recent multicenter RCT with 65 patients assessed the feasibility of a modifi ed ultrafi ltration in patients with CPB versus circulation without an interposed fi lter. Differences in RBC transfusions between groups did not reach statistical signifi cance, but introduction or increase in dose of vasopressors was more frequent in the modifi ed ultrafi ltration group [Boodhwani 2010] .
Because the impact of hemofi ltration on transfusions is currently unclear, routine ultrafi ltration during or immediately after CPB is considered not helpful for blood conservation in adult cardiac operations (Class III, level of evidence B) [Ferraris 2007] . Nevertheless, experienced perfusionists use hemofi ltration in selected cases in an attempt to reverse excessive hemodilution and improve fl uid balance, especially when response to diuretics is not satisfactory and/or a cell saver is not available.
PARENTERAL FLUID RESTRICTION
Because hemodilution is a major factor infl uencing the decision to transfuse in clinical practice, limiting hemodilution may reduce transfusions in cardiac operations involving CPB. Prime volume reduction, MC, RAP, hemofi ltration, and diuretics may be benefi cial in these operations mainly because they reduce extracellular volume expansion. Many practitioners attempt to limit positive fl uid balance by avoiding excessive parenteral fl uid administration. Surprisingly, data on the effect of intraoperative fl uid restriction on transfusion needs are very limited. Recently, a RCT involving 130 patients undergoing CABG under CPB reported signifi cant reduction of intraoperative PRC transfusions with a restrictive parenteral fl uid protocol, aided by near infra-red spectrophotoscopy (INVOS) [Vretzakis 2005] , and a more recent randomized trial evaluating the impact of fl uid restriction on blood transfusions demonstrated signifi cant reduction of intraoperative packed red cell transfusions in cardiac surgery patients treated with a fl uid restriction protocol. Transfusions in the intensive care unit (ICU) were not signifi cantly different, and discharge hematocrit did not differ signifi cantly between the restrictive and the liberal fl uid administration groups (Table 3 ) [Vretzakis 2010 ].
The role of newer monitoring technologies on decisionmaking during cardiac surgery deserves careful evaluation because every piece of information may help better assess the state of vital functions. In a prospective randomized trial, information from the bispectral index (BIS) monitor prompted intervention on a number of occasions during mild hypothermic CPB, but only 70% of these interventions targeted hypnotic state depth, whereas 30% of them addressed other aspects of patient care [Vretzakis 2005 ].
Most intraoperative transfusions occur during CPB, when SVO 2 monitoring with a pulmonary artery catheter is not feasible, and venous Hb saturation on venous cannula blood samples gives an inconclusive picture of tissue oxygenation because the heart is bypassed. In this setting, transfusion decisions are usually based on Hb values, using a predetermined "transfusion trigger." In reality, however, nobody knows what is best for a patient with low hematocrit (15% or less) during CPB. Is a blood transfusion needed/justifi ed when hematocrit is low, but brain tissue oxygen saturation, measured by INVOS, remains normal? Because the answer to this important question is unknown, we all hope that newer monitoring modalities will help decision-making by providing meaningful physiologic data. The impact of INVOS monitoring on allogeneic transfusions in cardiac surgery is currently under investigation (www.clinicaltrials.gov 00879463).
CONCLUSION
At the present time, several blood conservation interventions have been proposed during cardiac surgery, and a multimodal approach to blood conservation may be benefi cial, particularly in high-risk patients. The anesthesiologist has a signifi cant role during cardiac surgery; he can facilitate blood conservation efforts by limiting dilutional anemia through limitation of positive fl uid balance before or/and during CPB, but doing so requires coordination with the perfusionist and the cardiac surgeon.
Current evidence suggests that there is signifi cant room for improvement in physician transfusion practices during cardiac surgery. Appropriately designed rigorous clinical trials are needed to determine the effectiveness of intraoperative interventions on blood conservation and the role of new monitoring modalities in rational decision-making regarding blood product use in cardiac surgery.
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